Orietta Spinelli

Bergamo, 24127, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.

Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.

Journal: International journal of molecular sciences
Published: April 24, 2026

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Journal: Transplantation and cellular therapy
Published: April 14, 2026

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Journal: Clinical and experimental medicine
Published: March 27, 2026

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Journal: Bone marrow transplantation
Published: March 18, 2026

How deep is deep enough? The importance of the detection limits of the CML minimal residual disease gDNA assay.

How deep is deep enough? The importance of the detection limits of the CML minimal residual disease gDNA assay.

Journal: Cell death discovery
Published: March 05, 2026

Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement.

Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement.

Journal: Annals of hematology
Published: January 15, 2026

A novel KMT2A::AFF1-derived fusion circRNA regulates mitochondrial metabolism in t(4;11) B-cell acute lymphoblastic leukemia.

A novel KMT2A::AFF1-derived fusion circRNA regulates mitochondrial metabolism in t(4;11) B-cell acute lymphoblastic leukemia.

Journal: Haematologica
Published: December 30, 2025

Acute Hemolytic Anemia Following Rasburicase in a Very Late Post-Transplant Relapse of Acute Myeloid Leukemia.

Acute Hemolytic Anemia Following Rasburicase in a Very Late Post-Transplant Relapse of Acute Myeloid Leukemia.

Journal: Mediterranean journal of hematology and infectious diseases
Published: September 04, 2025

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

Journal: Blood cancer journal
Published: June 24, 2025

Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06.

Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06.

Journal: Leukemia research
Published: March 02, 2025

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.

Journal: Blood cancer journal
Published: December 17, 2024

Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.

Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.

Journal: Blood
Published: November 08, 2024
Showing 1-12 of 80

Last Updated: 09/26/2026